Table 1 Summary of COVID-19 patient demographics, laboratory results, pre-existing conditions, histopathological and macroscopic pathological features.
COVID-19 patients (n = 21) | |
|---|---|
Demographics | |
Age (years) | 64.3 (35–85) |
Male sex | 17 (81%) |
BMI (kg/m2) | 32.7 (22.0–48.0) |
Ventilator | 20 (95.2%) |
Lab results | |
Platelets (10E3/µL) | 232 (62–365) |
INR | 1.5 (1.0–2.6) |
PTT (s) | 40.9 (22.7–114.4) |
D-dimer (ng/mL) | 1222 (<215–3723) |
Troponin (ng/mL) | 0.08 (<0.04–0.13) |
Pre-existing conditions | |
Hypertension | 16 (76%) |
Hyperlipidemia | 11 (52%) |
Coronary artery disease | 5 (24%) |
Diabetes mellitus type II | 9 (43%) |
Chronic kidney disease | 6 (29%) |
Gastroesophageal reflux disease | 5 (24%) |
Histopathological features | |
Fibrosis | 9 (43%) |
Edema | 19 (90%) |
Borderline myocarditis | 19 (90%) |
Monocyte hypertrophy | 15 (71%) |
Myocytolysis | 10 (48%) |
Blood vessel congestion | 10 (48%) |
Thrombosis | 4 (19%) |
Hemorrhage | 4 (19%) |
Pericarditis | 2 (9.5%) |
Macroscopic pathological features | |
Average heart weight (g) | 447 (282–671) |
Right ventricular hypertrophy | 6 (29%) |
Left ventricular hypertrophy | 10 (48%) |
LAD narrowing (%) | 54 (0–90) |
LCA narrowing (%) | 48 (0–90) |
RCA narrowing (%) | 49 (0->90) |
Right ventricular dysfunction | 8 (38%) |
Left ventricular dysfunction | 5 (24%) |
Small vessel thrombi | 4 (19%) |
Lymph inflammation (myocardium) | 4 (19%) |
Lymph inflammation (epicardium) | 2 (10%) |
Acute myocardial infarction | 3 (14%) |
Hemorrhagic myocardial infarction | 6 (29%) |
